Johnson & Johnson Posts Blockbuster Q4 as Oncology and Immunology Drugs Fuel 9% Revenue Surge
Johnson & Johnson reports Q4 revenue of $24.6 billion, up 9.1%, driven by explosive growth in cancer and immunology treatments. Company projects $100.5B in 2026 sales.